Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Oxaliplatin, Capecitabine, and Radiation for Rectal Cancer
NCT00086931Phase 2Completed
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- Sep 2003
- Primary completion
- May 2007
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of oxaliplatin in rectal cancer, sponsored by Roswell Park Comprehensive Cancer Center. Primary endpoints: Maximum Tolerated Dose and Complete Pathological Response Rate. Started Sep 2003; status: completed.
02
Drugs
oxaliplatin
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT00086931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00086931.